Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 16 | $18,079,328 |
Sells | 30 | $12,713,728 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
17 Sep 2024 19:48 | TERN | Terns Pharmaceuticals Inc | LU HONGBO | Director | 12 Sep 2024 | Purchase | 285,714 | 10.5 | 2,999,997 | I |
17 Sep 2024 19:48 | TERN | Terns Pharmaceuticals Inc | LU HONGBO | Director | 12 Sep 2024 | Purchase | 190,476 | 10.5 | 1,999,998 | I |
12 Sep 2024 18:10 | TERN | Terns Pharmaceuticals Inc | VIGNOLA MARK J. | Chief Financial Officer | 10 Sep 2024 | Sale | 10,000 | 11 | 110,000 | D |
11 Sep 2024 18:00 | TERN | Terns Pharmaceuticals Inc | QUIGLEY JILL M. | Director | 09 Sep 2024 | Sale | 17,235 | 10 | 172,350 | D |
05 Aug 2024 20:11 | TERN | Terns Pharmaceuticals Inc | QUIGLEY JILL M. | Director | 02 Aug 2024 | Sale | 8,857 | 7.5005 | 66,432 | D |
05 Aug 2024 20:11 | TERN | Terns Pharmaceuticals Inc | QUIGLEY JILL M. | Director | 01 Aug 2024 | Sale | 6,143 | 7.6751 | 47,148 | D |
17 Jul 2024 20:53 | TERN | Terns Pharmaceuticals Inc | GORDON CARL L | Director , 10% | 16 Jul 2024 | Sale | 623 | 10 | 6,230 | I |
17 Jul 2024 20:53 | TERN | Terns Pharmaceuticals Inc | GORDON CARL L | Director , 10% | 16 Jul 2024 | Sale | 556 | 10 | 5,560 | I |
17 Jul 2024 20:53 | TERN | Terns Pharmaceuticals Inc | GORDON CARL L | Director , 10% | 16 Jul 2024 | Sale | 4,009 | 10 | 40,090 | I |
17 Jul 2024 20:53 | TERN | Terns Pharmaceuticals Inc | GORDON CARL L | Director , 10% | 15 Jul 2024 | Sale | 6,142 | 10 | 61,420 | I |
17 Jul 2024 20:53 | TERN | Terns Pharmaceuticals Inc | GORDON CARL L | Director , 10% | 15 Jul 2024 | Sale | 39,433 | 10 | 394,330 | I |
17 Jul 2024 20:53 | TERN | Terns Pharmaceuticals Inc | GORDON CARL L | Director , 10% | 15 Jul 2024 | Sale | 5,401 | 10 | 54,010 | I |
17 Jul 2024 20:48 | TERN | Terns Pharmaceuticals Inc | ORBIMED ADVISORS LLC | Director , 10% | 16 Jul 2024 | Sale | 623 | 10 | 6,230 | I |
17 Jul 2024 20:48 | TERN | Terns Pharmaceuticals Inc | ORBIMED ADVISORS LLC | Director , 10% | 16 Jul 2024 | Sale | 556 | 10 | 5,560 | I |
17 Jul 2024 20:48 | TERN | Terns Pharmaceuticals Inc | ORBIMED ADVISORS LLC | Director , 10% | 16 Jul 2024 | Sale | 4,009 | 10 | 40,090 | I |
17 Jul 2024 20:48 | TERN | Terns Pharmaceuticals Inc | ORBIMED ADVISORS LLC | Director , 10% | 15 Jul 2024 | Sale | 6,142 | 10 | 61,420 | I |
17 Jul 2024 20:48 | TERN | Terns Pharmaceuticals Inc | ORBIMED ADVISORS LLC | Director , 10% | 15 Jul 2024 | Sale | 5,401 | 10 | 54,010 | I |
17 Jul 2024 20:48 | TERN | Terns Pharmaceuticals Inc | ORBIMED ADVISORS LLC | Director , 10% | 15 Jul 2024 | Sale | 39,433 | 10 | 394,330 | I |
17 Jul 2024 19:56 | TERN | Terns Pharmaceuticals Inc | QUIGLEY JILL M. | Director | 16 Jul 2024 | Sale | 400 | 10 | 4,000 | D |
17 Jul 2024 19:56 | TERN | Terns Pharmaceuticals Inc | QUIGLEY JILL M. | Director | 15 Jul 2024 | Sale | 14,365 | 10.0007 | 143,660 | D |
04 Jun 2024 18:06 | TERN | Terns Pharmaceuticals Inc | YOON SEOKHO BRYAN | COO and General Counsel | 31 May 2024 | Purchase | 4,791 | 4.44 | 21,272 | D |
04 Jun 2024 18:05 | TERN | Terns Pharmaceuticals Inc | VIGNOLA MARK J. | Chief Financial Officer | 31 May 2024 | Purchase | 4,791 | 4.44 | 21,272 | D |
03 Apr 2024 20:47 | TERN | Terns Pharmaceuticals Inc | VIVO OPPORTUNITY, LLC | 10% | 03 Apr 2024 | Sale | 4,149 | 6.2 | 25,724 | I |
03 Apr 2024 20:47 | TERN | Terns Pharmaceuticals Inc | VIVO OPPORTUNITY, LLC | 10% | 03 Apr 2024 | Sale | 30,047 | 6.2 | 186,291 | I |
03 Apr 2024 20:47 | TERN | Terns Pharmaceuticals Inc | VIVO OPPORTUNITY, LLC | 10% | 03 Apr 2024 | Sale | 103,870 | 6.2 | 643,994 | I |
03 Apr 2024 20:47 | TERN | Terns Pharmaceuticals Inc | VIVO OPPORTUNITY, LLC | 10% | 02 Apr 2024 | Sale | 3,050 | 6.65 | 20,282 | I |
03 Apr 2024 20:47 | TERN | Terns Pharmaceuticals Inc | VIVO OPPORTUNITY, LLC | 10% | 02 Apr 2024 | Sale | 22,084 | 6.65 | 146,859 | I |
03 Apr 2024 20:47 | TERN | Terns Pharmaceuticals Inc | VIVO OPPORTUNITY, LLC | 10% | 02 Apr 2024 | Sale | 76,346 | 6.65 | 507,701 | I |
03 Apr 2024 20:47 | TERN | Terns Pharmaceuticals Inc | VIVO OPPORTUNITY, LLC | 10% | 01 Apr 2024 | Sale | 5,451 | 6.99 | 38,102 | I |
03 Apr 2024 20:47 | TERN | Terns Pharmaceuticals Inc | VIVO OPPORTUNITY, LLC | 10% | 01 Apr 2024 | Sale | 39,411 | 6.99 | 275,483 | I |
03 Apr 2024 20:47 | TERN | Terns Pharmaceuticals Inc | VIVO OPPORTUNITY, LLC | 10% | 01 Apr 2024 | Sale | 136,255 | 6.99 | 952,422 | I |
04 Dec 2023 18:03 | TERN | Terns Pharmaceuticals Inc | YOON SEOKHO BRYAN | COO and General Counsel | 30 Nov 2023 | Purchase | 743 | 3.78 | 2,809 | D |
04 Dec 2023 18:03 | TERN | Terns Pharmaceuticals Inc | VIGNOLA MARK J. | Chief Financial Officer | 30 Nov 2023 | Purchase | 743 | 3.78 | 2,809 | D |
02 Jun 2023 17:03 | TERN | Terns Pharmaceuticals Inc | VIGNOLA MARK J. | Chief Financial Officer | 31 May 2023 | Purchase | 9,997 | 1.41 | 14,096 | D |
02 Jun 2023 17:03 | TERN | Terns Pharmaceuticals Inc | YOON SEOKHO BRYAN | COO and General Counsel | 31 May 2023 | Purchase | 9,997 | 1.41 | 14,096 | D |
02 Jun 2023 17:03 | TERN | Terns Pharmaceuticals Inc | SUNDARAM SENTHIL VEL | Chief Executive Officer | 31 May 2023 | Purchase | 2,111 | 1.41 | 2,977 | D |
03 Feb 2023 18:01 | TERN | Terns Pharmaceuticals Inc | YOON SEOKHO BRYAN | COO and General Counsel | 30 Nov 2022 | Purchase | 3 | 1.41 | 4 | D |
03 Feb 2023 18:01 | TERN | Terns Pharmaceuticals Inc | VIGNOLA MARK J. | Chief Financial Officer | 30 Nov 2022 | Purchase | 3 | 1.41 | 4 | D |
03 Feb 2023 18:00 | TERN | Terns Pharmaceuticals Inc | SUNDARAM SENTHIL VEL | Chief Executive Officer | 30 Nov 2022 | Purchase | 3 | 1.41 | 4 | D |
28 Dec 2022 17:57 | TERN | Terns Pharmaceuticals Inc | ORBIMED ADVISORS LLC | Director , 10% | 23 Dec 2022 | Purchase | 137,931 | 7.25 | 1,000,000 | I |
28 Dec 2022 17:46 | TERN | Terns Pharmaceuticals Inc | GORDON CARL L | Director , 10% | 23 Dec 2022 | Purchase | 137,931 | 7.25 | 1,000,000 | I |
23 Dec 2022 17:48 | TERN | Terns Pharmaceuticals Inc | VIVO OPPORTUNITY, LLC | 10% | 23 Dec 2022 | Purchase | 758,620 | 7.25 | 5,499,995 | I |
23 Dec 2022 17:44 | TERN | Terns Pharmaceuticals Inc | LU HONGBO | Director | 23 Dec 2022 | Purchase | 758,620 | 7.25 | 5,499,995 | I |
28 Nov 2022 16:56 | TERN | Terns Pharmaceuticals Inc | LAV BIOSCIENCES FUND V, L.P. | 10% | 23 Nov 2022 | Sale | 166,666 | 5.5 | 916,663 | I |
28 Nov 2022 16:56 | TERN | Terns Pharmaceuticals Inc | LAV BIOSCIENCES FUND V, L.P. | 10% | 23 Nov 2022 | Sale | 333,334 | 5.5 | 1,833,337 | I |
28 Nov 2022 16:56 | TERN | Terns Pharmaceuticals Inc | LAV BIOSCIENCES FUND V, L.P. | 10% | 23 Nov 2022 | Sale | 1,000,000 | 5.5 | 5,500,000 | I |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)